Baxter 20 mmol Potassium Chloride, 5% Glucose and 0.45% Sodium Chloride injection for intravenous infusion 1000 mL bag (AHB6024) Australien - engelska - Department of Health (Therapeutic Goods Administration)

baxter 20 mmol potassium chloride, 5% glucose and 0.45% sodium chloride injection for intravenous infusion 1000 ml bag (ahb6024)

baxter healthcare pty ltd - potassium chloride, quantity: 1.49 g/l; glucose, quantity: 50 g/l; sodium chloride, quantity: 4.5 g/l - injection - excipient ingredients: water for injections - the potassium chloride, sodium chloride and glucose intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Baxter 20 mmol Potassium Chloride, 5% Glucose and 0.9% Sodium Chloride injection for intravenous infusion 1000 mL bag (AHB6066) Australien - engelska - Department of Health (Therapeutic Goods Administration)

baxter 20 mmol potassium chloride, 5% glucose and 0.9% sodium chloride injection for intravenous infusion 1000 ml bag (ahb6066)

baxter healthcare pty ltd - potassium chloride, quantity: 1.49 g/l; glucose, quantity: 50 g/l; sodium chloride, quantity: 9 g/l - injection - excipient ingredients: water for injections - the potassium chloride, sodium chloride and glucose intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

BAXTER 0.15% POTASSIUM CHLORIDE AND 0.225% SODIUM CHLORIDE AND 3.75% GLUCOSE 500mL injection BP Australien - engelska - Department of Health (Therapeutic Goods Administration)

baxter 0.15% potassium chloride and 0.225% sodium chloride and 3.75% glucose 500ml injection bp

baxter healthcare pty ltd - glucose, quantity: 37.5 g/l; sodium chloride, quantity: 2.25 g/l; potassium chloride, quantity: 1.5 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the potassium chloride ( 0.15%) and sodium chloride (0.225 %) and glucose (3.75 %) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

BAXTER 0.15% Potassium Chloride and 0.18% SODIUM CHLORIDE and 4% GLUCOSE 1000mL injection BPAHB1704 Australien - engelska - Department of Health (Therapeutic Goods Administration)

baxter 0.15% potassium chloride and 0.18% sodium chloride and 4% glucose 1000ml injection bpahb1704

baxter healthcare pty ltd - potassium chloride, quantity: 1.5 g/l; sodium chloride, quantity: 1.8 g/l; glucose, quantity: 40 g/l - injection, solution - excipient ingredients: water for injections - the potassium chloride ( 0.15%) and sodium chloride (0.18 %) and glucose (4 %) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

BAXTER 0.244% POTASSIUM CHLORIDE and 0.18% SODIUM CHLORIDE and 4% GLUCOSE 1000mL injection AHB1224 Australien - engelska - Department of Health (Therapeutic Goods Administration)

baxter 0.244% potassium chloride and 0.18% sodium chloride and 4% glucose 1000ml injection ahb1224

baxter healthcare pty ltd - glucose, quantity: 40 g/l; potassium chloride, quantity: 2.24 g/l; sodium chloride, quantity: 1.8 g/l - injection, solution - excipient ingredients: water for injections - the potassium chloride (0.224%), sodium chloride (0.18%), and glucose (4%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

BAXTER 0.224% POTASSIUM CHLORIDE and 5% GLUCOSE 1000mL injection AHB1174 Australien - engelska - Department of Health (Therapeutic Goods Administration)

baxter 0.224% potassium chloride and 5% glucose 1000ml injection ahb1174

baxter healthcare pty ltd - glucose, quantity: 50 g/l; potassium chloride, quantity: 2.24 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the potassium chloride in glucose (5%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of potassium and chloride ion concentrations. this is also an alternative route of administration for the patients who are unable to take potassium orally or if hypokalaemia is severe. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

BAXTER 0.15% POTASSIUM CHLORIDE and 5% GLUCOSE 1L Injection BP AHB1134 Australien - engelska - Department of Health (Therapeutic Goods Administration)

baxter 0.15% potassium chloride and 5% glucose 1l injection bp ahb1134

baxter healthcare pty ltd - glucose, quantity: 50 g/l; potassium chloride, quantity: 1.5 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the potassium chloride in glucose (5%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of potassium and chloride ion concentrations. this is also an alternative route of administration for the patients who are unable to take potassium orally or if hypokalaemia is severe. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Bleomycin Baxter 15 000 KY injektio/infuusiokuiva-aine, liuosta varten Finland - finska - Fimea (Suomen lääkevirasto)

bleomycin baxter 15 000 ky injektio/infuusiokuiva-aine, liuosta varten

baxter oy - bleomycin sulfate - injektio/infuusiokuiva-aine, liuosta varten - 15 000 ky - bleomysiini

Pemetrexed Baxter Europeiska unionen - svenska - EMA (European Medicines Agency)

pemetrexed baxter

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiska medel - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Pemetrexed Baxter Europeiska unionen - polska - EMA (European Medicines Agency)

pemetrexed baxter

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - Środki przeciwnowotworowe - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.